Perrigo Suffers As It Waves Goodbye To Rx

CEO Kessler Acknowledges ‘Disappointing’ Q3 As Prescription Business Divested

Perrigo CEO Murray Kessler has acknowledged “disappointing” third quarter results for the company during a transitional quarter that saw it finally divest its Rx prescription generics business ahead of its upcoming acquisition of consumer healthcare specialist HRA Pharma.

Hand sign arrivals departures
Perrigo says goodbye to the Rx business as it waits to absorb HRA • Source: Alamy

Perrigo CEO Murray Kessler has insisted that the company has a “bright future” despite acknowledging “disappointing third quarter results [that] reflect the continuing impacts of the challenging operating environment caused by the global COVID-19 pandemic.”

[Sidebar#GB151066]

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Earnings

More from Business